Alzamend Neuro (ALZN) 10-Q 15 Mar 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jan. 31, 2022	Mar. 15, 2022
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--04-30
Entity File Number	001-40483
Entity Registrant Name	ALZAMEND NEURO, INC.
Entity Central Index Key	0001677077
Entity Tax Identification Number	81-1822909
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3500 Lenox Rd NE
Entity Address, Address Line Two	Suite 1500
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30326
City Area Code	(844)
Local Phone Number	722-6303
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ALZN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,102,623
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	3802 Spectrum Boulevard
Entity Address, Address Line Two	Suite 112C
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33612

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
CURRENT ASSETS
Cash	$ 11,790,289	$ 1,929,270
Prepaid expenses and other current assets	638,827	983,320
TOTAL CURRENT ASSETS	12,429,116	2,912,590
TOTAL ASSETS	12,429,116	2,912,590
CURRENT LIABILITIES
Accounts payable and accrued liabilities	464,895	503,593
Related party payable	2,082	60,749
Convertible notes, net		335,303
TOTAL CURRENT LIABILITIES	466,977	899,645
STOCKHOLDERS’ EQUITY
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil and 750,000 shares issued and outstanding as of January 31, 2022 and April 30, 2021, respectively		75
Common stock, $0.0001 par value: 300,000,000 shares authorized; 90,102,623 and 67,429,525 shares issued and outstanding as of January 31, 2022 and April 30, 2021 respectively	9,010	6,743
Additional paid-in capital	52,161,522	33,721,859
Note receivable for common stock – related party	(14,883,295)	(14,883,295)
Accumulated deficit	(25,325,098)	(16,832,437)
TOTAL STOCKHOLDERS’ EQUITY	11,962,139	2,012,945
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 12,429,116	$ 2,912,590

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jan. 31, 2022	Apr. 30, 2021
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares, outstanding		90,102,623
Common Stock, Shares, Issued	90,102,623
Shares, Issued	67,429,525
Shares, Outstanding		67,429,525
Series A Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	8,640,000
Preferred Stock Shares Designated	1,360,000	1,360,000
Preferred stock, shares outstanding	750,000	750,000
Shares, Outstanding		750,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
OPERATING EXPENSES
Research and development	$ 873,653	$ 234,262	$ 3,540,111	$ 1,018,021
General and administrative	1,682,913	881,397	4,906,628	2,713,891
Total operating expenses	2,556,566	1,115,659	8,446,739	3,731,912
Loss from operations	(2,556,566)	(1,115,659)	(8,446,739)	(3,731,912)
OTHER INCOME (EXPENSE), NET
Interest expense	(16,299)	(57,366)	(45,922)	(108,181)
Interest expense - related party		(8,277)		(13,765)
Interest income - related party				1,706
Gain on extinguishment of debt		62,418		62,418
Total other income (expense), net	(16,299)	(3,225)	(45,922)	(57,822)
NET LOSS	$ (2,572,865)	$ (1,118,884)	$ (8,492,661)	$ (3,789,734)
Basic and diluted net loss per common share	$ (0.03)	$ (0.02)	$ (0.09)	$ (0.05)

Condensed Statements of Stockho

Condensed Statements of Stockholders Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Note Recievable for Common Stock Related Party [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Apr. 30, 2020	$ 75	$ 6,476	$ 27,584,227	$ (14,983,200)	$ (11,785,869)	$ 821,709
Shares outstanding biginning balance at Apr. 30, 2020	750,000	64,762,858
Stock-based compensation to employees and consultants			1,479,231			1,479,231
Shares outstanding ending balance	750,000
Net loss					(3,789,734)	(3,789,734)
Proceeds from note receivable – related party for common stock				99,905		99,905
Fair value of warrants issued in connection with convertible notes			78,642			78,642
Fair value of warrants issued in connection with convertible notes- related party			14,300			14,300
Ending balance, value at Jan. 31, 2021	$ 75	$ 6,476	29,156,400	(14,883,295)	(15,575,603)	(1,295,947)
Shares outstanding ending balance at Jan. 31, 2021	750,000	64,762,858
Beginning balance, value at Oct. 31, 2020	$ 75	$ 6,476	28,666,695	(14,883,295)	(14,456,719)	(666,768)
Shares outstanding biginning balance at Oct. 31, 2020	750,000	64,762,858
Stock-based compensation to employees and consultants			489,705			489,705
Net loss					(1,118,884)	(1,118,884)
Ending balance, value at Jan. 31, 2021	$ 75	$ 6,476	29,156,400	(14,883,295)	(15,575,603)	(1,295,947)
Shares outstanding ending balance at Jan. 31, 2021	750,000	64,762,858
Beginning balance, value at Apr. 30, 2021	$ 75	$ 6,743	33,721,859	(14,883,295)	(16,832,437)	$ 2,012,945
Shares outstanding biginning balance at Apr. 30, 2021	750,000	67,429,525				67,429,525
Stock-based compensation to employees and consultants			3,150,801			$ 3,150,801
Proceeds from stock option exercise		$ 300	900			1,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		3,000,000
Conversion of Series A convertible stock	$ (75)	$ 1,500	(1,425)
Shares outstanding ending balance	(750,000)	15,000,000
Net loss					(8,492,661)	(8,492,661)
Issuance of common stock for restricted stock awards		21	(21)
Stock Issued During Period, Shares, New Issues						212,500
Proceeds from sale of common stock and warrants-related party, net		$ 133	1,999,867			$ 2,000,000
Stock Issued During Period Shares New Issues2		1,333,333
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million		$ 288	12,911,168			12,911,456
Stock Issued During Period Shares New Issues3		2,875,000
Issuance of shares of common stock for conversion of note		$ 25	378,373			378,398
Issuance of Shares of Common Stock for Conversion of Debt Shares		252,265
Ending balance, value at Jan. 31, 2022		$ 9,010	52,161,522	(14,883,295)	(25,325,098)	11,962,139
Shares outstanding ending balance at Jan. 31, 2022		90,102,623
Beginning balance, value at Oct. 31, 2021		$ 8,885	50,652,054	(14,883,295)	(22,752,233)	13,025,411
Shares outstanding biginning balance at Oct. 31, 2021		88,850,358
Stock-based compensation to employees and consultants			1,130,795			1,130,795
Proceeds from stock option exercise		$ 100	300			400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		1,000,000
Conversion of Series A convertible stock		$ 25	378,373			378,398
Shares outstanding ending balance		252,265
Net loss					(2,572,865)	(2,572,865)
Ending balance, value at Jan. 31, 2022		$ 9,010	$ 52,161,522	$ (14,883,295)	$ (25,325,098)	$ 11,962,139
Shares outstanding ending balance at Jan. 31, 2022		90,102,623

Condensed Statements of Stock_2

Condensed Statements of Stockholders Equity (Deficit) (Unaudited) (Parenthetical)	9 Months Ended
	Jan. 31, 2022USD ($)
Statement of Stockholders' Equity [Abstract]
Proceeds from Issuance Initial Public Offering	$ 1,500,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Cash flows from operating activities:
Net loss	$ (8,492,661)	$ (3,789,734)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest expense - debt discount	12,770	97,446
Interest expense - debt discount, related party		12,088
Gain on extinguishment of debt		(62,418)
Stock-based compensation to employees and consultants	3,150,801	1,735,497
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	344,493	605,279
Accounts payable and accrued expenses	(67,040)	(52,312)
Net cash used in operating activities	(5,051,637)	(1,454,154)
Cash flows from investing activities:
Proceeds from repayments of notes receivable - related party		100,915
Net cash provided by investing activities		100,915
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants - related party, net	2,000,000
Proceeds from stock option exercise	1,200
Advances from related party payable		1,676
Proceeds from short-term advances, related party		800,000
Proceeds from note payable		62,110
Proceeds from note receivable for common stock – related party		99,905
Proceeds from convertible note payable		290,000
Proceeds from convertible note payable, related party		50,000
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs	12,911,456
Net cash provided by financing activities	14,912,656	1,303,691
Net increase (decrease) in cash	9,861,019	(49,548)
Cash at beginning of period	1,929,270	90,285
Cash at end of period	11,790,289	40,737
Non-cash financing activities:
Fair value of warrants issued in connection with initial public offering	461,877
Fair value of warrants issued in connection with convertible notes payable, related party	4,799,742	14,300
Fair value of warrants issued in connection with convertible notes payable		78,642
Issuance of common stock on conversion of note	$ 378,373

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Organization Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s”). With two current and future product candidates, Alzamend aims to bring treatments and/or potential cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc. (the “Licensor”), and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license with Licensor The Company is devoting substantially all its efforts towards research and development of its Technology. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $ 0.0001 Initial Public Offering On June 14, 2021, the Company’s registration statement on Form S-1 (File No. 333-255955) for its initial public offering of Common Stock (“IPO”) was declared effective by the Securities and Exchange Commission (“SEC”). On June 15, 2021, the Company issued and sold 2,875,000 5.00 2,000,000 In connection with the closing of the IPO, all of the Company’s outstanding shares of Series A convertible preferred stock (the “Series A Preferred Shares”) were converted into 15,000,000

LIQUIDITY AND GOING CONCERN

LIQUIDITY AND GOING CONCERN	9 Months Ended
	Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN	2. LIQUIDITY AND GOING CONCERN The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern. As of January 31, 2022, the Company had cash of $ 11.8 million 2.6 million 8.5 million The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash and cash equivalents at January 31, 2022, are sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2021, filed with the SEC on July 29, 2021. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Annual Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2021 has been derived from the audited balance sheet at April 30, 2021 contained in such Form 10-K. Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2022 and April 30, 2021, the Company had no cash equivalents. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to clinical research organizations that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different. Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging , Debt Issued with Warrants The Company considers guidance within ASC 470-20, Debt In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are allocated to the warrants and convertible debt based on their relative estimated fair values. The allocated fair value of equity warrants is recorded as a discount to the convertible debt with a corresponding increase to additional paid-in capital. The debt discount is amortized as interest expense using the effective interest method. Embedded Derivatives. Beneficial Conversion Feature. Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, warrants and convertible preferred stock are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share For the Nine Months Ended January 31, 2022 2021 Series A convertible preferred stock - 15,000,000 Stock options (1) 13,500,000 16,300,000 Warrants 8,830,785 6,769,635 Convertible notes - 245,999 22,330,785 38,315,634 (1) The Company has excluded 4,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

NOTE RECEIVABLE FOR COMMON STOC

NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY	9 Months Ended
	Jan. 31, 2022
Note Receivable For Common Stock Related Party
NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY	4. NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY On April 30, 2019, the Company and Ault Life Sciences Fund, LLC (“ALSF”) entered into a Securities Purchase Agreement (“SPA”) for the purchase of 10,000,000 15,000,000 5,000,000 5 3.00 14,883,295

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Jan. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets are as follows January 31, 2022 April 30, 2021 Prepaid consulting fees $ 256,667 $ 966,260 Prepaid insurance 370,179 - Other prepaid expenses 11,981 850 Other receivables - 16,210 Total prepaid expenses and other current assets $ 638,827 $ 983,320 On June 14, 2021, the Company purchased directors and officers insurance for 12 months at an annual premium amount of $ 855,000

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	6. STOCK-BASED COMPENSATION 2016 Stock Incentive Plan On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 12,500,000 7,500,000 five 10 2021 Stock Incentive Plan In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Stock Subject to the 2021 Plan. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. A summary of stock option activity for the nine months ended January 31, 2022, is presented below: Outstanding Options Weighted Weighted Average Shares Average Remaining Aggregate Available for Number of Exercise Contractual Intrinsic Grant Options Price Life (years) Value Balance at April 30, 2021 10,450,000 19,550,000 $ 0.7195 5.92 $ 35,159,500 Options granted (1,750,000 ) 1,750,000 $ 2.9171 Options exercised - (3,000,000 ) $ 0.0004 Options cancelled/forfeited 300,000 (300,000 ) $ 1.5000 Balance at January 31, 2022 9,000,000 18,000,000 $ 0.9826 6.00 $ 13,118,800 Options vested and expected to vest at January 31, 2022 16,000,000 $ 1.0418 6.41 $ 1 0,529,200 Options exercisable at January 31, 2022 13,460,519 $ 0.7891 5.87 $ 9,806,358 The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. Stock Options Granted to Employees and Consultants The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Nine Months Ended January 31, 2022 2021 Expected term (in years) 3.50 6.25 6.25 Volatility 85.53 87.10 100.10 Risk-free interest rate 1.01 1.07 0.51 Dividend yield 0.0 0.0 Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend: Stock-based compensation to employees and consultants from stock option grants for the nine months ended January 31, 2022 and 2021 were $ 3.2 million 1.7 million Performance Contingent Stock Options Granted to Employee In November 2018, the Board granted 2,000,000 1.00 These options have two separate performance triggers for vesting based upon the therapies achieving certain Food and Drug Administration (“FDA”) approval milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent awards is $ 1.2 million On November 26, 2019, the Board granted 4,250,000 In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of January 31, 2022, Performance Contingent Stock Options Granted to Consultants - TAMM Net On March 23, 2021, the Company issued performance-based stock options to the certain team members at TAMM Net, Inc. to purchase an aggregate of 450,000 As of January 31, 2022, the Company believes the performance goal of completing Phase I clinical trial of AL001 will be achieved. The Company is recognizing stock compensation related to the completion of Phase I clinical trial of AL001 by March 31, 2022 over the implied service period expected to complete this milestone. Due to the significant risks and uncertainties associated with achieving the completion of Phase I for AL002, as of January 31, 2022, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to AL002. Performance Contingent Stock Options Granted to Consultants -Other Consultants On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication, AL001 for a PTSD indication, AL001 for a depression indication and AL002 for an Alzheimer’s indication. As of January 31, 2022, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to Phase II of AL001 and AL002. Stock-Based Compensation Expense The Company’s results of operations include expenses relating to stock-based compensation for the three and nine months ended January 31, 2022 and 2021, was comprised as follows: For the Three Months Ended For the Nine Months Ended 2022 2021 2022 2021 Research and development $ 106,102 $ 21,813 $ 359,286 $ 65,439 General and administrative 1,024,693 553,314 2,791,515 1,670,058 Total $ 1,130,795 $ 575,127 $ 3,150,801 $ 1,735,497 As of January 31, 2022, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $ 5.2 million. 1.9

WARRANTS

WARRANTS	9 Months Ended
	Jan. 31, 2022
Warrants
WARRANTS	7. WARRANTS During the nine months ended January 31, 2022, the Company issued warrants to purchase an aggregate of 727,917 3.00 6.25 (i) On June 17 2021, the Company issued a warrant to purchase an aggregate of 61,250 6.25 (ii) On July 28, 2021, the Company received from the U.S. Food and Drug Administration a “Study May Proceed” letter for a Phase I study under the Company’s Investigational New Drug application for AL001. Based on the achievement of this milestone, the Company sold an additional 1,333,333 2 1.50 3.00 The following table summarizes information about Common Stock warrants outstanding at January 31, 2022: Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $ 1.00 500,000 2.3 $ 1.00 500,000 $ 1.00 $ 1.75 175,672 3.0 $ 1.75 175,672 $ 1.75 $ 3.00 8,093,863 3.1 $ 3.00 8,093,863 $ 3.00 $ 6.25 61,250 4.6 $ 6.25 61,250 $ 6.25 $ 1.00 6.25 8,830,785 3.1 $ 2.88 8,830,785 $ 2.88 The estimated fair value of warrants granted during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Nine Months Ended January 31, 2022 2021 Expected term (in years) 5.00 5.00 Volatility 86.31% 103.70% Risk-free interest rate 0.87 0.90 0.27 0.28 Dividend yield 0.0% 0.0% Expected Term: Expected Volatility: Risk-Free Interest Rate: Expected Dividend:

OTHER RELATED PARTY TRANSACTION

OTHER RELATED PARTY TRANSACTIONS	9 Months Ended
	Jan. 31, 2022
Related Party Transactions [Abstract]
OTHER RELATED PARTY TRANSACTIONS	8. OTHER RELATED PARTY TRANSACTIONS In March 2021, the Company entered into the SPA with DPL pursuant to which the Company agreed to sell an aggregate of 6,666,667 10 DPL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by BitNile Holdings, Inc (“BitNile“), for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase I clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of the Phase I clinical trials for AL001 for a purchase price of $4 million The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of January 31, 2022 In May 2021, the Board and Mr. Milton C. Ault, the Company’s Founder and Chairman Emeritus, agreed to certain arrangements with regard to Board composition and other matters. Contemporaneously with the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the resignation by Mr. Ault as a director and executive officer of the Company 5 50,000 50,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Contractual Obligations On May 1, 2016, the Company entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012. In addition to royalty payments of 4 Original AL001 License: Payment Due Date Event $ 65,000 Paid in November 2021 IND application filing $ 190,000 Paid in November 2021 Upon first dosing of patient in a clinical trial $ 500,000 12 months from first patient dosing Upon Completion of first clinical trial $ 1,250,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 8 years from the effective date of the agreement Upon FDA approval AL002 License: Payment Due Date Event $ 50,000 Upon IND application filing Upon IND application filing $ 50,000 12 months from IND application filing date Upon first dosing of patient in first Phase I clinical trial $ 175,000 12 months from first patient dosed in Phase I Upon completion of first Phase I clinical trial $ 500,000 24 months from completion of first Phase I clinical trial Upon completion of first Phase II clinical trial $ 1,000,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 7 years from the effective date of the agreement Upon FDA BLA approval If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive license agreements with Sublicensing Terms, both effective July 2, 2018 (the “AL001 license agreements”) with Licensor and the University of South Florida. In addition, a royalty payment of 3% is required pursuant to License #18110 while License #1811 requires a royalty payment of 1.5% on net sales of products developed from the licensed technology. Additionally, the Company is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows: Additional AL001 Licenses: Payment Due Date Event $ 50,000 December 31, 2022 IND application filing $ 150,000 12 months from IND filing date Upon first dosing of patient in a clinical trial $ 400,000 12 months from first patient dosing Upon Completion of first clinical trial $ 1,000,000 36 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 8,000,000 8 years from the effective date of the agreement First commercial sale

CONVERTIBLE NOTES

CONVERTIBLE NOTES	9 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	10. CONVERTIBLE NOTES In February 2021, the Company entered into the SPA with an institutional investor to sell a convertible promissory note in the aggregate principal amount of $ 348,000 335,000 10 1.50 The fair value of equity warrants was recorded as a discount to the convertible promissory note with a corresponding increase to additional paid-in capital. The Company computed the estimated fair value of the warrants using the Black-Scholes option pricing model and, as a result of this calculation, recorded debt discount in the amount of $ 13,000 0.27 103.7 137,000 46,000

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	9 Months Ended
	Jan. 31, 2022
Equity [Abstract]
EQUITY TRANSACTIONS	11. EQUITY TRANSACTIONS The Company is authorized to issue 10,000,000 0.0001 1,360,000 8,640,000 Series A Preferred Shares In connection with the closing of the IPO, all of the outstanding Series A Preferred Shares were converted into 15,000,000 shares of Common Stock. As of January 31, 2022, there were no Series A Preferred Shares or other shares of Preferred Stock issued or outstanding. Common Stock On April 30, 2019, the Company and ALSF entered into a SPA for the purchase of 10,000,000 15,000,000 1.50 5,000,000 5 3.00 15,000,000 12 In March 2021, the Company entered into the SPA with DPL pursuant to which the Company agreed to sell an aggregate of 6,666,667 10 1.50 4 1.8 50,000 2,666,667 DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase Ia clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of these Phase Ia clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $ 10 10

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jan. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that warrant disclosure or recognition in the condensed financial statements presented herein.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2021, filed with the SEC on July 29, 2021. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Annual Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2021 has been derived from the audited balance sheet at April 30, 2021 contained in such Form 10-K.
Accounting Estimates	Accounting Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2022 and April 30, 2021, the Company had no cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. The fair values of warrants issued in connection with equity or debt issuance are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of the underlying Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to clinical research organizations that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the satisfaction of the performance conditions as of the reporting date. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.
Warrants	Warrants The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging ,
Debt Issued with Warrants	Debt Issued with Warrants The Company considers guidance within ASC 470-20, Debt In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of convertible debt are allocated to the warrants and convertible debt based on their relative estimated fair values. The allocated fair value of equity warrants is recorded as a discount to the convertible debt with a corresponding increase to additional paid-in capital. The debt discount is amortized as interest expense using the effective interest method. Embedded Derivatives. Beneficial Conversion Feature.
Loss per Common Share	Loss per Common Share The Company utilizes FASB ASC Topic No. 260, Earnings per Share Since the effects of outstanding options, warrants and convertible preferred stock are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share For the Nine Months Ended January 31, 2022 2021 Series A convertible preferred stock - 15,000,000 Stock options (1) 13,500,000 16,300,000 Warrants 8,830,785 6,769,635 Convertible notes - 245,999 22,330,785 38,315,634 (1) The Company has excluded 4,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share	The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share For the Nine Months Ended January 31, 2022 2021 Series A convertible preferred stock - 15,000,000 Stock options (1) 13,500,000 16,300,000 Warrants 8,830,785 6,769,635 Convertible notes - 245,999 22,330,785 38,315,634 (1) The Company has excluded 4,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Jan. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other current assets are as follows	Prepaid expenses and other current assets are as follows January 31, 2022 April 30, 2021 Prepaid consulting fees $ 256,667 $ 966,260 Prepaid insurance 370,179 - Other prepaid expenses 11,981 850 Other receivables - 16,210 Total prepaid expenses and other current assets $ 638,827 $ 983,320

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
A summary of stock option activity for the nine months ended January 31, 2022, is presented below:	A summary of stock option activity for the nine months ended January 31, 2022, is presented below: Outstanding Options Weighted Weighted Average Shares Average Remaining Aggregate Available for Number of Exercise Contractual Intrinsic Grant Options Price Life (years) Value Balance at April 30, 2021 10,450,000 19,550,000 $ 0.7195 5.92 $ 35,159,500 Options granted (1,750,000 ) 1,750,000 $ 2.9171 Options exercised - (3,000,000 ) $ 0.0004 Options cancelled/forfeited 300,000 (300,000 ) $ 1.5000 Balance at January 31, 2022 9,000,000 18,000,000 $ 0.9826 6.00 $ 13,118,800 Options vested and expected to vest at January 31, 2022 16,000,000 $ 1.0418 6.41 $ 1 0,529,200 Options exercisable at January 31, 2022 13,460,519 $ 0.7891 5.87 $ 9,806,358
The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions:	The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Nine Months Ended January 31, 2022 2021 Expected term (in years) 3.50 6.25 6.25 Volatility 85.53 87.10 100.10 Risk-free interest rate 1.01 1.07 0.51 Dividend yield 0.0 0.0
The Company’s results of operations include expenses relating to stock-based compensation for the three and nine months ended January 31, 2022 and 2021, was comprised as follows:	The Company’s results of operations include expenses relating to stock-based compensation for the three and nine months ended January 31, 2022 and 2021, was comprised as follows: For the Three Months Ended For the Nine Months Ended 2022 2021 2022 2021 Research and development $ 106,102 $ 21,813 $ 359,286 $ 65,439 General and administrative 1,024,693 553,314 2,791,515 1,670,058 Total $ 1,130,795 $ 575,127 $ 3,150,801 $ 1,735,497

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Jan. 31, 2022
Warrants
The following table summarizes information about Common Stock warrants outstanding at January 31, 2022:	The following table summarizes information about Common Stock warrants outstanding at January 31, 2022: Outstanding Exercisable Weighted Average Weighted Weighted Remaining Average Average Exercise Number Contractual Exercise Number Exercise Price Outstanding Life (years) Price Exercisable Price $ 1.00 500,000 2.3 $ 1.00 500,000 $ 1.00 $ 1.75 175,672 3.0 $ 1.75 175,672 $ 1.75 $ 3.00 8,093,863 3.1 $ 3.00 8,093,863 $ 3.00 $ 6.25 61,250 4.6 $ 6.25 61,250 $ 6.25 $ 1.00 6.25 8,830,785 3.1 $ 2.88 8,830,785 $ 2.88
The estimated fair value of warrants granted during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions:	The estimated fair value of warrants granted during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: For the Nine Months Ended January 31, 2022 2021 Expected term (in years) 5.00 5.00 Volatility 86.31% 103.70% Risk-free interest rate 0.87 0.90 0.27 0.28 Dividend yield 0.0% 0.0%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Original AL001 License:	Original AL001 License: Payment Due Date Event $ 65,000 Paid in November 2021 IND application filing $ 190,000 Paid in November 2021 Upon first dosing of patient in a clinical trial $ 500,000 12 months from first patient dosing Upon Completion of first clinical trial $ 1,250,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 8 years from the effective date of the agreement Upon FDA approval AL002 License: Payment Due Date Event $ 50,000 Upon IND application filing Upon IND application filing $ 50,000 12 months from IND application filing date Upon first dosing of patient in first Phase I clinical trial $ 175,000 12 months from first patient dosed in Phase I Upon completion of first Phase I clinical trial $ 500,000 24 months from completion of first Phase I clinical trial Upon completion of first Phase II clinical trial $ 1,000,000 12 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 10,000,000 7 years from the effective date of the agreement Upon FDA BLA approval If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive license agreements with Sublicensing Terms, both effective July 2, 2018 (the “AL001 license agreements”) with Licensor and the University of South Florida. In addition, a royalty payment of 3% is required pursuant to License #18110 while License #1811 requires a royalty payment of 1.5% on net sales of products developed from the licensed technology. Additionally, the Company is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows: Additional AL001 Licenses: Payment Due Date Event $ 50,000 December 31, 2022 IND application filing $ 150,000 12 months from IND filing date Upon first dosing of patient in a clinical trial $ 400,000 12 months from first patient dosing Upon Completion of first clinical trial $ 1,000,000 36 months from completion of the first Phase II clinical trial Upon first patient treated in a Phase III clinical trial $ 8,000,000 8 years from the effective date of the agreement First commercial sale

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares	Jun. 15, 2021	Jan. 31, 2022	Apr. 30, 2021
Subsidiary, Sale of Stock [Line Items]
Description of novel products		The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s”). With two current and future product candidates, Alzamend aims to bring treatments and/or potential cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc. (the “Licensor”), and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license with Licensor
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Issuance of common stock for restricted stock awards (in shares)		212,500
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding		750,000	750,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock for restricted stock awards (in shares)	2,875,000
Public offering price	$ 5
IPO [Member] | Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding		15,000,000
IPO [Member] | Digital Power Lending [Member]
Subsidiary, Sale of Stock [Line Items]
Stock ipo purchased	2,000,000

LIQUIDITY AND GOING CONCERN (De

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 11,800,000		$ 11,800,000
Net Income (Loss) Attributable to Parent	$ (2,572,865)	$ (1,118,884)	$ (8,492,661)	$ (3,789,734)

The following sets forth the nu

The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share (Details) - shares		9 Months Ended
		Jan. 31, 2022	Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		22,330,785	38,315,634
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	[1]	13,500,000	16,300,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		8,830,785	6,769,635
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			245,999
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	15,000,000
[1]	The Company has excluded 4,500,000 stock options, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

NOTE RECEIVABLE FOR COMMON ST_2

NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) - USD ($)	Apr. 30, 2019	Jan. 31, 2022	Apr. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Number of shares purchase (in shares)		212,500
Number of shares purchase
Warrant terms		3 years 1 month 6 days
Outstanding receivable amount			$ 14,883,295
Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares purchase (in shares)	10,000,000
Number of shares purchase	$ 15,000,000
Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of warrants granted	5,000,000
Warrant terms	5 years
Exercise price (in dollars per share)	$ 3

Prepaid expenses and other cu_3

Prepaid expenses and other current assets are as follows (Details) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting fees	$ 256,667	$ 966,260
Prepaid insurance	370,179
Other prepaid expenses	11,981	850
Other receivables		16,210
Total prepaid expenses and other current assets	$ 638,827	$ 983,320

PREPAID EXPENSES AND OTHER CU_4

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)	Jun. 14, 2021USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Purchase D&O Insurance	$ 855,000

A summary of stock option activ

A summary of stock option activity for the nine months ended January 31, 2022, is presented below: (Details)	9 Months Ended
	Jan. 31, 2022USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Balance at Begining	10,450,000
Balance at Begining	19,550,000
Balance at Begining | $ / shares	$ 0.7195
Balance at Begining	5 years 11 months 1 day
Balance at Begining | $	$ 35,159,500
Options Granted	(1,750,000)
Options Granted	1,750,000
Options Granted | $ / shares	$ 2.9171
Options exercised	(3,000,000)
Options exercised | $ / shares	$ 0.0004
Options cnacelled/forfieted	300,000
Options cancelled/forfeited	(300,000)
Options cancelled/forfeited | $ / shares	$ 1.5000
Balance at End	9,000,000
Balance at End	18,000,000
Balance at End | $ / shares	$ 0.9826
Balance at End	5 years 11 months 19 days
Balance at End | $	$ 13,118,800
Options vested and expected to vest at end	16,000,000
Options vested and expected to vest at end | $ / shares	$ 1.0418
Options vested and expected to vest at end	6 years 6 months 10 days
Options vested and expected to vest at end | $	$ 1
Options exercisable at end	13,460,519
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.7891
Options exercisable at end	5 years 10 months 17 days
Options exercisable at end | $	$ 9,806,358

The estimated fair value of sto

The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)	9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member] | Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Term (in years)	3 years 6 months
Volatility	85.53%
Risk-free interest rate	1.01%
Maximum [Member] | Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Term (in years)	6 years 2 months 30 days	6 years 2 months 30 days
Volatility	87.10%	100.10%
Risk-free interest rate	1.07%	0.51%

The Company_s results of operat

The Company’s results of operations include expenses relating to stock-based compensation for the three and nine months ended January 31, 2022 and 2021, was comprised as follows: (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,130,795	$ 575,127	$ 3,150,801	$ 1,735,497
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	106,102	21,813	359,286	65,439
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,024,693	$ 553,314	$ 2,791,515	$ 1,670,058

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Mar. 23, 2021	Nov. 26, 2019	Mar. 01, 2019	Apr. 30, 2016	Nov. 30, 2018	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						$ 1,130,795	$ 575,127	$ 3,150,801	$ 1,735,497
Options granted								1,750,000
Exercise price (in dollars per share)								$ 2.9171
Options vested and expected to vest						16,000,000		16,000,000
Weighted-average period vested and expected to vest at end								6 years 6 months 10 days
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						$ 1,024,693	$ 553,314	$ 2,791,515	1,670,058
Unamortized Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period vested and expected to vest at end								1 year 10 months 25 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation								$ 3,200,000	$ 1,700,000
Performance Contingent Stock Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					2,000,000
Exercise price (in dollars per share)					$ 1
Performance Contingent Stock Options [Member] | Key Employees and Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	450,000	4,250,000
Terms of award		In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of January 31, 2022,
Minimum [Member] | Performance Contingent Stock Options [Member] | General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation					$ 1,200,000
Stock Incentive Plan2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				12,500,000
Additional number of shares available for issuance			7,500,000
Stock Incentive Plan2016 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				5 years
Stock Incentive Plan2016 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				10 years

The following table summarizes

The following table summarizes information about Common Stock warrants outstanding at January 31, 2022: (Details)	Jan. 31, 2022$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number warrant outstanding | shares	8,830,785
Weighted average remaining contractual life (years)	3 years 1 month 6 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 2.88
Number of warrant exercisable | shares	8,830,785
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 2.88
Exercise Price 1 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 1
Number warrant outstanding | shares	500,000
Weighted average remaining contractual life (years)	2 years 3 months 19 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1
Number of warrant exercisable | shares	500,000
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1
Exercise Price 2 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 1.75
Number warrant outstanding | shares	175,672
Weighted average remaining contractual life (years)	3 years
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 1.75
Number of warrant exercisable | shares	175,672
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 1.75
Exercise Price 3 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 3
Exercise Price Fifty Six [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number warrant outstanding | shares	8,093,863
Weighted average remaining contractual life (years)	3 years 1 month 6 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 3
Number of warrant exercisable | shares	8,093,863
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 3
Exercise Price 4 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	6.25
Exercise Price 4 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	1
Exercise Price 4 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercse price (in dollars per share)	$ 6.25
Exercise Price Fifty Seven [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number warrant outstanding | shares	61,250
Weighted average remaining contractual life (years)	4 years 7 months 6 days
Warrant outstanding, weighted average exercise price (in dollars per share)	$ 6.25
Number of warrant exercisable | shares	61,250
Warrant exercisable, weighted average exercise price (in dollars per share)	$ 6.25

The estimated fair value of war

The estimated fair value of warrants granted during the nine months ended January 31, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details) - Number	Jan. 31, 2022	Jan. 31, 2021
Expected term (in years)	3 years 1 month 6 days
Warrant [Member]
Expected term (in years)	5 years	5 years
Warrant [Member] | Measurement Input, Option Volatility [Member]
Warrants measurement input	86.31	103.70
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants measurement input	0.87	0.27
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants measurement input	0.90	0.28
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Minimum [Member]
Warrants measurement input	0	0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member] - USD ($) $ / shares in Units, $ in Millions	Jul. 28, 2021	Jun. 17, 2021	Jan. 31, 2022	Jul. 28, 2020
Number of stock repurchase		61,250	727,917
Exercise price (in dollars per share)		$ 6.25	$ 6.25	$ 3
D P L [Member]
Number of stock repurchase	1,333,333
Exercise price (in dollars per share)	$ 1.50
Amount of stock repurchase	$ 2
Minimum [Member]
Exercise price (in dollars per share)			$ 3

OTHER RELATED PARTY TRANSACTI_2

OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jun. 15, 2021	Mar. 09, 2021	May 31, 2021	Mar. 31, 2021
William Horne [Member]
Related Party Transaction [Line Items]
Number of shares issued for services, value			$ 50,000
IPO [Member] | Mr Ault [Member]
Related Party Transaction [Line Items]
Description of conversion			the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the resignation by Mr. Ault as a director and executive officer of the Company
Percentage of outstanding common shares			5.00%
Digital Power Lending [Member] | IPO [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares)	2,000,000
Securities Purchase Agreement [Member] | Digital Power Lending [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares)				6,666,667
Number of shares sold				$ 10,000,000
Description of related party transaction		DPL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by BitNile Holdings, Inc (“BitNile“), for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase I clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of the Phase I clinical trials for AL001 for a purchase price of $4 million
Description of milestones				The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of January 31, 2022
Consulting Agreement [Member] | IPO [Member] | Mr Ault [Member]
Related Party Transaction [Line Items]
Advisory and consulting services fees			$ 50,000,000,000

Original AL001 License_ (Detail

Original AL001 License: (Details)	9 Months Ended
	Jan. 31, 2022USD ($)
A L001 License [Member] | ind Application Filing [Member]
Product Liability Contingency [Line Items]
Payment	$ 65,000
Due Date	Paid in November 2021
A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 190,000
Due Date	Paid in November 2021
A L001 License [Member] | Upon Completion of First Patient Dosing [Member]
Product Liability Contingency [Line Items]
Payment	$ 500,000
Due Date	12 months from first patient dosing
A L001 License [Member] | Upon Completion of First Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 1,250,000
Due Date	12 months from completion of the first Phase II clinical trial
A L001 License [Member] | Upon Fda Approval [Member]
Product Liability Contingency [Line Items]
Payment	$ 10,000,000
Due Date	8 years from the effective date of the agreement
A L002 License [Member] | ind Application Filing [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due Date	12 months from IND application filing date
A L002 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 175,000
Due Date	12 months from first patient dosed in Phase I
A L002 License [Member] | Upon Completion of First Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 500,000
Due Date	24 months from completion of first Phase I clinical trial
A L002 License [Member] | Upon Fda Approval [Member]
Product Liability Contingency [Line Items]
Payment	$ 10,000,000
Due Date	7 years from the effective date of the agreement
A L002 License [Member] | Pre ind Meeting [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due Date	Upon IND application filing
A L002 License [Member] | Upon First Patient Treated in Phase3 Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 1,000,000
Due Date	12 months from completion of the first Phase II clinical trial
Additional A L001 License [Member] | ind Application Filing [Member]
Product Liability Contingency [Line Items]
Payment	$ 50,000
Due Date	December 31, 2022
Additional A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 150,000
Due Date	12 months from IND filing date
Additional A L001 License [Member] | Upon Completion of First Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 400,000
Due Date	12 months from first patient dosing
Additional A L001 License [Member] | Upon Fda Approval [Member]
Product Liability Contingency [Line Items]
Payment	$ 8,000,000
Due Date	8 years from the effective date of the agreement
Additional A L001 License [Member] | Upon First Patient Treated in Phase3 Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment	$ 1,000,000
Due Date	36 months from completion of the first Phase II clinical trial

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	6 Months Ended	9 Months Ended
	Oct. 31, 2021	Jan. 31, 2022
Additional A L001 License [Member]
Product Liability Contingency [Line Items]
Percentage of Royalty Payments on Net Sales of Product.	4.00%
A L001 License [Member]
Product Liability Contingency [Line Items]
Description of Licenses Aggregate		In addition, a royalty payment of 3% is required pursuant to License #18110 while License #1811 requires a royalty payment of 1.5% on net sales of products developed from the licensed technology. Additionally, the Company is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)	1 Months Ended	9 Months Ended
	Feb. 28, 2021USD ($)$ / shares	Jan. 31, 2022USD ($)$ / shares	Jan. 31, 2021USD ($)	Apr. 30, 2021Number$ / shares
Short-term Debt [Line Items]
Number of shares purchase
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001
Debt discount		$ 12,770	$ 97,446
Convertible Promissory Note Twelve [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Debt instrument measurement input | Number				0.27
Convertible Promissory Note Twelve [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Debt instrument measurement input | Number				103.7
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Debt discount		13,000
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt discount		137,000
Original issue discount		$ 46,000
Securities Purchase Agreement [Member] | Institutional Investor [Member] | Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount	$ 348,000
Number of shares purchase	$ 335,000
Interest rate	10.00%
Common stock, par value (in dollars per share) | $ / shares	$ 1.50

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	Mar. 09, 2021	Apr. 30, 2019	Mar. 31, 2021	Jul. 31, 2021	Jan. 31, 2022	Jun. 17, 2021	Apr. 30, 2021	Jan. 31, 2021	Jul. 28, 2020
Class of Stock [Line Items]
Preferred Stock, Shares Authorized					10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share					$ 0.0001		$ 0.0001
Warrant terms					3 years 1 month 6 days
Warrant [Member]
Class of Stock [Line Items]
Warrant terms					5 years			5 years
Exercise price (in dollars per share)					$ 6.25	$ 6.25			$ 3
A L S F [Member]
Class of Stock [Line Items]
Shares purchase price		$ 15,000,000
Warrant terms		12 months
Securities Purchase Agreements [Member] | A L S F [Member]
Class of Stock [Line Items]
Number of shares purchase		10,000,000
Shares purchase price		$ 15,000,000
Shares purchase price (in dollars per share)		$ 1.50
Securities Purchase Agreements [Member] | A L S F [Member] | Warrant [Member]
Class of Stock [Line Items]
Number of shares purchase		5,000,000
Warrant terms		5 years
Exercise price (in dollars per share)		$ 3
Securities Purchase Agreements [Member] | Digital Power Lending [Member]
Class of Stock [Line Items]
Number of shares issued			6,666,667
Proceeds from sale of equity			$ 10,000,000
Shares issued price per share			$ 1.50
Proceeds from related party	$ 4,000,000
Advance from related parties	$ 1,800,000
Description of purchase agreement terms			DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase Ia clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of these Phase Ia clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]
Class of Stock [Line Items]
Additional right to invest			$ 10,000,000	$ 10,000,000
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]
Class of Stock [Line Items]
Number of shares issued	2,666,667
Shares value surrender for cancellation	$ 50,000,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized					8,640,000
Preferred Stock, Par or Stated Value Per Share					$ 0.0001		$ 0.0001
Preferred Stock Shares Designated					1,360,000		1,360,000